AbbVie Inc (ABBV)

Currency in USD
208.42
-1.84(-0.88%)
Closed·
208.420.00(0.00%)
·

AbbVie (ABBV) Earnings Dates & Reports

Latest Release
Feb 04, 2026
EPS / Forecast
2.71 / 2.65
Revenue / Forecast
16.62B / 16.39B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/2.86--/14.72B----Free Sign Up
12/20252.71/2.6516.62B/16.39B+2.26%+1.4%Free Sign Up
09/20251.86/1.7815.78B/15.58B+4.49%+1.28%Free Sign Up
06/20252.97/2.9615.42B/14.99B+0.34%+2.87%Free Sign Up
03/20250.720/2.3913.34B/12.93B-69.87%+3.17%Free Sign Up
12/20242.16/2.0615.10B/14.82B+4.85%+1.89%Free Sign Up
09/20243.00/2.9214.46B/14.28B+2.74%+1.26%Free Sign Up
06/20242.65/2.7014.46B/14.02B-1.85%+3.14%Free Sign Up
03/20242.31/2.2712.31B/11.93B+1.76%+3.19%Free Sign Up
12/20232.79/2.7714.30B/14.01B+0.72%+2.07%Free Sign Up

All numbers in USD

AbbVie Inc Earnings Call Summary for Q4/2025

  • AbbVie exceeded Q4 2025 forecasts with EPS of $2.71 and revenue of $16.62 billion, yet stock fell 6.45% due to concerns over Humira sales erosion and economic challenges.
  • The company achieved 8.6% sales growth despite a $16 billion decline in Humira sales, with full-year adjusted EPS reaching $10, exceeding initial guidance by $0.54.
  • CEO Rob Michael expressed confidence in AbbVie's momentum, projecting 9.5% sales growth for 2026 with full-year adjusted EPS expected between $14.37 and $14.57.
  • Strategic acquisitions and increased R&D investments have positioned AbbVie for sustained growth, focusing on expanding its product portfolio in key therapeutic areas.
Last Updated: 02/04/2026, 10:55 AM
Read Full Transcript

FAQ

What Is AbbVie's Earnings Per Share (TTM)?

The AbbVie EPS (TTM) is 2.36.

When Is The Next AbbVie Earnings Date?

AbbVie will release its next earnings report on Apr 29, 2026.

What Is AbbVie’s Revenue Forecasts For Upcoming Quarters?

AbbVie’s revenue forecast is 14.72B.

How Did AbbVie React to the Company's Latest Earnings Report?

AbbVie reported a +2.26% EPS surprise and a +1.4% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -2.94%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.